The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Flagged first, then by citations
1 of the 56 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 944
Battaglin, F., Ou, F., Qu, X., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Ashouri, K., Zemla, T., Blanke, C. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01507 · Cited by 21
Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies
Angelis, M. L. D., Bruselles, A., Francescangeli, F., Pucilli, F., Vitale, S., Zeuner, A., Tartaglia, M., & Baiocchi, M. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-018-9423-3 · Cited by 22
O’Farrell, A. C., Jarzabek, M. A., Lindner, A. U., Carberry, S., Conroy, E., Miller, I. S., Connor, K., Shiels, L., Zanella, E. R., Lucantoni, F., et al. (2020) · Cancers · doi:10.3390/cancers12102978 · Cited by 20
Self-citationBiomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 25
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Nguyen, L. V., & Caldas, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013189 · Cited by 19
Glenny, E. M., Coleman, M. F., Giles, E. D., Wellberg, E. A., & Hursting, S. D. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120420-032437 · Cited by 18
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Yoshikawa, A., & Nakamura, Y. (2022) · Cancers · doi:10.3390/cancers15010183 · Cited by 21
A review on emerging targeted therapies for the management of metastatic colorectal cancers
Deshmukh, R., Prajapati, M. K., & Harwansh, R. K. (2023) · Medical Oncology · doi:10.1007/s12032-023-02020-x · Cited by 19
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals
Zheng-Lin, B., & Bekaii‐Saab, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225037 · Cited by 24
Challenges and opportunities for cell line secretomes in cancer proteomics
Méndez, O., & Villanueva, J. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400131 · Cited by 20
Wang, J., Xing, B., Liu, W., Li, J., Wang, X., Li, J., Yang, J., Ji, C., Li, Z., Dong, B., et al. (2019) · Theranostics · doi:10.7150/thno.32033 · Cited by 19
Li, M., Yue, G. G., Luo, L., Tsui, S. K., Fung, K., Ng, S. S. M., & Lau, C. B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574827 · Cited by 19
Patient-derived xenograft models for oncology drug discovery
Li, G. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.152769 · Cited by 19
Single-cell sequencing and organoids: applications in organ development and disease
Li, T., Yin, J., Hao, Y., Gao, W., Li, Q., Feng, Q., Tao, B., Hao, M., Liu, Y., Lin, C., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00364-6 · Cited by 20
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 18
Tang, X., Gong, J., Ren, L., Wang, Z., Yang, B., Wang, W., & Wang, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117037 · Cited by 18
Amendt, C., Staub, E., Friese‐Hamim, M., Störkel, S., & Stroh, C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3385 · Cited by 18
Chen, M., Yang, S., Li, F., Wu, L., Chen, R., Chang, J. H., & Hu, J. (2019) · Pancreas · doi:10.1097/mpa.0000000000001398 · Cited by 18
Seligmann, J. F., Elliott, F., Richman, S. D., Hemmings, G., Brown, S., Jacobs, B., Williams, C. J. M., Tejpar, S., Barrett, J. H., Quirke, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.476 · Cited by 18
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0211 · Cited by 18
Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer
Shiovitz, S., & Grady, W. M. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0431-7 · Cited by 18
Pauw, I. D., Wouters, A., den Bossche, J. V., Peeters, M., Pauwels, P., Deschoolmeester, V., Vermorken, J. B., & Lardon, F. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.014 · Cited by 17
Huang, H., Zhou, Y., Shang, C., Zhang, Y., & Shen, Y. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01507-w · Cited by 20
Bozym, D. J., Zheng, D. X., Revach, O., Aref, A. R., & Jenkins, R. W. (2025) · Lab on a Chip · doi:10.1039/d5lc00062a · Cited by 20
Aprile, G., Maglio, G. D., Menis, J., Casagrande, M., Tuniz, F., Pisa, F. E., Fontanella, C., Škrap, M., Beltrami, A., Fasola, G., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022370 · Cited by 17
Drug Discovery Oncology in a Mouse: concepts, Models and Limitations
Long, J. E., Jankovic, M., & Maddalo, D. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0019 · Cited by 17
Pauw, I. D., Lardon, F., den Bossche, J. V., Baysal, H., Pauwels, P., Peeters, M., Vermorken, J. B., & Wouters, A. (2019) · Cancers · doi:10.3390/cancers11010098 · Cited by 17
Wei, Q., Zhang, Y., Gao, J., Li, J., Li, J., Li, Y., Zhou, J., Lu, M. S., Gong, J., Zhang, X., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.05.001 · Cited by 17
Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo
Azizian, N. G., Sullivan, D. K., Nie, L., Pardo, S., Molleur, D., Chen, J., Weintraub, S. T., & Li, Y. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00666 · Cited by 17
Owen, D. R., Wong, H., Bonakdar, M., Jones, M. R., Hughes, C. S., Morin, G. B., Jones, S. J. M., Renouf, D. J., Lim, H. J., Laskin, J. J., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002535 · Cited by 17
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 18
Mauri, G., Durinikova, E., Amatu, A., Tosi, F., Cassingena, A., Rizzetto, F., Buzo, K., Arcella, P., Aquilano, M. C., Bonoldi, E., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00143 · Cited by 19
Self-citationWang, C., Sandhu, J. S., & Fakih, M. (2022) · The Oncologist · doi:10.1093/oncolo/oyab028 · Cited by 16
Hagemann, I. S., Bridge, J. A., Tafe, L. J., Hameed, M., Moncur, J. T., Bellizzi, A. M., Dolan, M., Vasalos, P., Kane, M. E., Souers, R. J., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0229-cp · Cited by 17
Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17
Self-citationNapolitano, S., Martini, G., Martinelli, E., Belli, V., Parascandolo, A., Laukkanen, M. O., Sforza, V., Morgillo, F., Ciardiello, D., Ciardiello, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18749 · Cited by 16
Park, J. E., Jin, M. H., Hur, M., Nam, A., Bang, J., Won, J., Oh, D., & Bang, Y. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00943-x · Cited by 16
Li, Z., Chen, Y., Ren, W., Hu, S., Tan, Z.-L., Wang, Y., Chen, Y., Zhang, J., Wu, J., Li, T., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20126 · Cited by 15
A Biobank of Colorectal Cancer Patient-Derived Xenografts
Abdirahman, S. M., Christie, M., Preaudet, A., Burstroem, M. C. U., Mouradov, D., Lee, B., Sieber, O. M., & Putoczki, T. L. (2020) · Cancers · doi:10.3390/cancers12092340 · Cited by 16
Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
Qiu, M., He, C., Yang, X., Yang, L., Lin, J., Zhou, D., Long, Y., Guan, W., Jin, Y., Li, Y., et al. (2021) · The Oncologist · doi:10.1002/onco.13786 · Cited by 18
Tseng, C.-H., Huang, W., Chew, C. H., Lai, J.-K., Tu, S., Wei, P., Lee, K., Lai, G., & Chen, C. (2019) · Materials · doi:10.3390/ma12040569 · Cited by 16
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00926-7 · Cited by 16
Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer
de Groot, R. A., Reedijk, D., Faucher, Q., Mihaila, S. M., & Masereeuw, R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00412.2025 · Cited by 19
Mouse models in the era of large human tumour sequencing studies
de Ruiter, J. R., Wessels, L. F. A., & Jonkers, J. (2018) · Open Biology · doi:10.1098/rsob.180080 · Cited by 16
Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models
Xiang, K., Wang, E., Mantyh, J. B., Rupprecht, G., Negrete, M., Sanati, G., Hsu, C., Randon, P. M., Dohlman, A. B., Kretzschmar, K., et al. (2024) · Advanced Science · doi:10.1002/advs.202303379 · Cited by 15
Hurdles on the road to personalized medicine
Tursz, T., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.009 · Cited by 16
Li, J., Ye, C., & Mansmann, U. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2401 · Cited by 14
Pertuzumab in gastrointestinal cancer
Oh, D., & Bang, Y. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1126578 · Cited by 15
Beyond precision surgery: Molecularly motivated precision care for gastric cancer
Choi, Y. Y., & Cheong, J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.02.013 · Cited by 15
Zhao, S. G., Yu, M., Spratt, D. E., Chang, S. L., Feng, F. Y.-C., Kim, M. M., Speers, C. W., Carlson, B. L., Mladek, A. C., Lawrence, T. S., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz090 · Cited by 17
Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M., Sers, C., Morkel, M., Schwab, M. G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0818 · Cited by 15
Oswald, E., Bug, D., Grote, A., Lashuk, K., Bouteldja, N., Lenhard, D., Löhr, A., Behnke, A., Knauff, V., Edinger, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004412 · Cited by 14
Barry, G. S., Cheang, M. C. U., Chang, H. L., & Kennecke, H. F. (2016) · Oncotarget · doi:10.18632/oncotarget.8006 · Cited by 15
Park, J. S., Yoon, G., Kim, H. J., Park, S. Y., Choi, G., Kang, M. K., Kim, J. G., Jang, J.-S., & Seo, A. N. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2409-y · Cited by 15
What Role could Organoids Play in the Personalization of Cancer Treatment?
Francies, H. E., & Garnett, M. J. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.114 · Cited by 15
Karan, C., Tan, E. S., Sarfraz, H. R., Knepper, T. C., Walko, C. M., Felder, S. I., Kim, R. D., & Şahin, İ. H. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00904 · Cited by 15
Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes
Menéndez, J. A., Alarcón, T., Corominas-Faja, B., Cuyàs, E., López‐Bonet, E., Martín, Á. G., & Vellón, L. (2014) · Cell Cycle · doi:10.4161/cc.27770 · Cited by 14
Cignetto, S., Modica, C., Chiriaco, C., Fontani, L., Milla, P., Michieli, P., Comoglio, P. M., & Vigna, E. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.03.004 · Cited by 14
Self-citationPrimary and acquired resistance to biologic therapies in gastrointestinal cancers
Lubner, S. J., Uboha, N. V., & Deming, D. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.16 · Cited by 14
Zheng, P., Liang, C., Ren, L., Zhu, D., Feng, Q., Chang, W., He, G., Ye, L., Chen, J., Lin, Q., et al. (2018) · Journal of Oncology · doi:10.1155/2018/5072987 · Cited by 14
Development of Patient-Derived Tumor Xenograft Models
Annibali, D., Leucci, E., Hermans, E., & Amant, F. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8769-6_15 · Cited by 14
Bottarelli, L., Angelis, G. L. D., Azzoni, C., Mario, F. D., de’Angelis, N., Leandro, G., Fornaroli, F., Gaiani, F., & Negri, F. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i9-s.7881 · Cited by 14
Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
Bañobre, J. R., & Goel, A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.008 · Cited by 15
Hall, J. C., Marlow, L. A., Mathias, A. C., Dawson, L. K., Durham, W. F., Meshaw, K. A., Mullin, R. J., Synnott, A. J., Small, D. L., Krishna, M., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0875-z · Cited by 14
Ni, S., Wang, X., Chang, J., Sun, H., Weng, W., Wang, X., Tan, C., Zhang, M., Wang, L., Huang, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842787 · Cited by 14
Wang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 14
Translational research of new developments in targeted therapy of colorectal cancer
Yang, L., Atakhanova, N. E., Arellano, M. T. C., Mohamed, M. Y., Hani, T., Fahdil, A. A., Castillo-Acobo, R. Y., Juyal, A., Hussein, A. K., Amin, A. H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154888 · Cited by 14
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
Pizzamiglio, M., Soulabaille, A., Lahlou, W., Pilla, L., Zaanan, A., & Taı̈eb, J. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115471 · Cited by 16
Comparative mutational landscape analysis of patient-derived tumour xenografts
Brait, M., Izumchenko, E., Kagohara, L. T., Long, S., Wysocki, P., Faherty, B., Fertig, E. J., Khor, T. O., Bruckheimer, E. M., Baía, G. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.450 · Cited by 14
Kovalchuk, A., Ilnytskyy, Y., Rodriguez‐Juarez, R., Katz, A. M., Sidransky, D., Kolb, B. E., & Kovalchuk, O. (2017) · Oncotarget · doi:10.18632/oncotarget.19835 · Cited by 13
Huang, F., Liang, X., Min, X., Zhang, Y., Wang, B., Peng, Z., Peng, F., Li, M., Chen, L., & Chen, Y. (2019) · Journal of Cancer · doi:10.7150/jca.29327 · Cited by 13
Lindner, A. U., Carberry, S., Monsefi, N., Barat, A., Salvucci, M., O’Byrne, R., Zanella, E. R., Cremona, M., Hennessy, B. T., Bertotti, A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33226 · Cited by 12
Self-citationZiranu, P., Lai, E., Schirripa, M., Puzzoni, M., Persano, M., Pretta, A., Munari, G., Liscia, N., Pusceddu, V., Loupakis, F., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00816-3 · Cited by 15
Jo, H., Yagishita, S., Hayashi, Y., Ryu, S., Suzuki, M., Kohsaka, S., Ueno, T., Matsumoto, Y., Horinouchi, H., Ohe, Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0371 · Cited by 13
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
Rosati, G., Aprile, G., Colombo, A., Cordio, S. S., Giampaglia, M., Cappetta, A., Porretto, C. M., Stefano, A. D., Bilancia, D., & Avallone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051035 · Cited by 14
Recent advances in the development of transplanted colorectal cancer mouse models
Yang, Y.-S., Liu, C.-Y., Wen, D., Gao, D.-Z., Lin, S., He, H., & Zhao, X.-F. (2022) · Translational research · doi:10.1016/j.trsl.2022.07.003 · Cited by 13
Subbiah, V. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0401-5 · Cited by 13
Miele, E., Abballe, L., Spinelli, G. P., Besharat, Z. M., Catanzaro, G., Chiacchiarini, M., Vacca, A., Pò, A., Capalbo, C., & Ferretti, E. (2020) · BMC Cancer · doi:10.1186/s12885-020-6586-0 · Cited by 13
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 14
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 17
Singh, H., Sahgal, P., Kapner, K. S., Corsello, S. M., Gupta, H. V., Gujrathi, R., Li, Y. Y., Cherniack, A. D., Alam, R. E., Kerfoot, J. A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2581 · Cited by 14
Self-citationPrognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas
Quaquarini, E., Grillo, F., Gervaso, L., Arpa, G., Fazio, N., Vanoli, A., & Parente, P. (2024) · Cancers · doi:10.3390/cancers16183145 · Cited by 13
Kovalchuk, A., Ilnytskyy, Y., Rodriguez‐Juarez, R., Katz, A. M., Sidransky, D., Kolb, B. E., & Kovalchuk, O. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00058 · Cited by 12
Mouse Models of Germinal Center Derived B-Cell Lymphomas
Meyer, S. N., Koul, S., & Pasqualucci, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710711 · Cited by 18
Gao, M., Jiang, T., Li, P., Zhang, J., Xu, K., & Ren, T. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106330 · Cited by 12
Lawler, T., Parlato, L., & Andersen, S. W. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01783-y · Cited by 12
How the Lab is Changing Our View of Colorectal Cancer
Cremolini, C., & Pietrantonio, F. (2016) · Tumori Journal · doi:10.5301/tj.5000551 · Cited by 12
Fakih, M. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0436 · Cited by 12
Baraibar, I., Ros, J., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Cuadra‐Urteaga, J. L., Sardo, E., Ciardiello, D., Tabernero, J. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1782194 · Cited by 13
Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer
Mohamadzade, Z., Mahjoubi, F., & Soltani, B. M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05937-3 · Cited by 13
Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts
Moy, R. H., Walch, H. S., Mattar, M. S., Chatila, W. K., Molena, D., Strong, V. E., Tang, L. H., Maron, S. B., Coit, D. G., Jones, D. R., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00242 · Cited by 12
Troiani, T., Martinelli, E., Morgillo, F., Capasso, A., Nappi, A. G., Sforza, V., & Ciardiello, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012462462 · Cited by 12
Development of Preclinical Models to Understand and Treat Colorectal Cancer
Sebolt, J. S. (2018) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0037-1602240 · Cited by 12
Vaghi, C., Tosi, F., Mauri, G., Bonazzina, E., Amatu, A., Bencardino, K., Piscazzi, D., Roazzi, L., Villa, F., Maggi, M., et al. (2026) · Drugs · doi:10.1007/s40265-025-02253-2 · Cited by 11
Self-citationPharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer
Gonzalez, N. S., López-Valbuena, D., Gómez, D., Ros, J., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2160316 · Cited by 11
Factors associated with engraftment success of patient-derived xenografts of breast cancer
Lee, J., Lee, G., Park, H. S., Jeong, B.-K., Gong, G., Jeong, J. H., & Lee, H. J. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01794-w · Cited by 11
Zhang, R., Su, C., Jia, Y.-L., Xing, M., Jin, S., & Zong, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117363 · Cited by 16
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
